Highlights Brii Biosciences Limited

Equities

2137

KYG1645A1094

Market Closed - Hong Kong S.E. Other stock markets 01:38:08 27/06/2024 pm IST			5-day change	1st Jan Change
1.02 ^HKD	-3.77%		-8.93%	-55.26%

10/06	Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference	MT
07/06	Brii Biosciences Limited Announces New Data from Two Phase 2 Studies Evaluating BRII-179	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference	10/06	MT
Brii Biosciences Limited Announces New Data from Two Phase 2 Studies Evaluating BRII-179	07/06	CI
Brii Bio's Hepatitis B Drugs Get Breakthrough Therapy Designation in China	15/05	MT
Brii Biosciences Limited Announces Center for Drug Evaluation of the National Medical Products Administration of China Grants Breakthrough Therapy Designations for BRII-877 and BRII-835	14/05	CI
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023	14/11	CI
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B	06/23/06	CI
Brii Biosciences Limited Announces Data from Interim Analysis of A Randomized, Placebo-Controlled and Double-Blinded Phase 2 Study of Brii-179	06/23/06	CI
Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023	22/23/22	CI
Shionogi Inc. completed the acquisition of Qpex Biopharma, Inc. from Brii Biosciences Limited and Others.	31/23/31	CI
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties	06/23/06	CI
Brii Biosciences to Acquire Development, Commercialization Rights on Bacterial Drug in Greater China; Shares Up 4%	26/23/26	MT
Shionogi Inc. entered into a definitive agreement to acquire Qpex Biopharma, Inc. from Brii Biosciences Limited and Others for $140 million.	26/23/26	CI
Brii Biosciences Limited Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating BRII-297	01/23/01	CI
Brii Biosciences' Loss Narrows Down in 2022	24/23/24	MT
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Brii Biosciences Limited Announces Interim Findings from A Phase 2 Study	15/23/15	CI
Brii Biosciences Limited Provides Update on Strategic Clinical Development Progress	27/22/27	CI
Brii Biosciences Announces New Data from Two Phase 1 Studies	19/22/19	CI
Brii Biosciences Limited Announces Topline Results from a Phase 1 Study Evaluating its Long-Acting, Single-Injection Therapy, BRII-296, in the Development for the Treatment of Postpartum Depression	26/22/26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Brii Biosciences Limited

Equities

2137

KYG1645A1094

Highlights

Filters